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TO THE EDITOR
A unique property of myeloid lineage leukemia cells is their potential to be differentiated into dendritic cells (DC), both in vitro and in vivo. These leukemic DC have potential therapeutic applications, such as stimulation of autologous anti leukemia T-cell responses in leukemia patients, or allogeneic responses in the post bone marrow transplantation (BMT) setting. Several studies have demonstrated that leukemic cells from a proportion of patients with acute myeloid leukemia (AML) 1 or chronic myeloid leukemia (CML) 2 can be differentiated into functionally active DC capable of inducing antileukemia T-cell responses. 3, 4 We were interested in the utilization of such an immunotherapeutic approach for patients with juvenile myelomonocytic leukemia (JMML), a rare condition with poor prognosis. This approach is attractive because allogeneic BMT is considered necessary for cure, and the graft-versus-leukemia (GVL) effect is critically important. 5, 6 We initially assessed whether immature DC could be generated in vitro from plastic adherent peripheral blood mononuclear cells (PBMC) from three JMML patients (JMML-1, -2, -3). After 6 days of culture with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) in the presence of 10% fetal calf serum, cells from normal donors and all three JMML patients demonstrated a typical immature monocyte-derived DC (MoDC) surface phenotype. This was inferred from their high expression levels of the myeloid marker CD11c, intermediate levels of the MHC class II molecule HLA-DR and the costimulatory molecule CD86 (B7-2), and undetectable levels of the dendritic activation marker CD83 and the monocytic marker CD14 (Figure 1 ). Typically, 10 ml of peripheral blood from JMML patients yielded about 5 Â 10 7 adherent cells and the final yield of viable MoDC was between 25 and 50% of this starting population. The cells generated from normal donors and JMML patients formed nonadherent clusters and possessed short cytoplasmic projections, characteristic of immature DC morphology. 7 Immature DC are specialized at capturing and processing antigens; however, optimal presentation of potential leukemiaspecific antigens to T lymphocytes requires that the DC are in an activated, mature state. 7 Therefore, we next attempted to activate the in vitro cultured immature DC with lipopolysaccharide (LPS). Immature DC populations generated from normal, JMML-1, and JMML-2 PBMC upregulated HLA-DR, CD83 and CD86 expression following 24-h exposure to LPS, acquiring a mature dendritic phenotype ( Figure 1 ). These mature DC therefore expressed the necessary cell surface molecules required for efficient antigen presentation and costimulation. However, the DC cultured from JMML-3 PBMC failed to upregulate HLA-DR and CD83 following addition of LPS (data not shown).
The leukemic cells in two of the patients (JMML-2 and -3) exhibited monosomy 7, a commonly observed chromosomal abnormality of this disease. We were able to use this as a marker of malignant origin, and interphase fluorescence in situ hybridization (FISH) analysis revealed that the vast majority of CD86 + -purifed mature DC generated from these patients displayed monosomy 7 (98% of JMML-2 DC and 91% of JMML-3 DC). In contrast, DC cultured from PBMC from a normal donor all possessed two copies of chromosome 7. This finding confirmed that virtually all the DC cultured in vitro from these JMML patients were of leukemic origin.
Several experiments were performed to investigate the functional activity of these leukemic DC. Limited sample sizes prevented us from examining the functional activity of DC cultured from all three JMML patients in each assay. To examine further the ability of in vitro cultured DC to provide the costimulatory signal required to activate naïve T cells, we measured DC production of IL-12 by ELISA (Becton Dickinson, San Diego, CA, USA). Secretion of IL-12 by mature DC is required for T-cell activation, and is associated with a Th-1 response. Consistent with published data, immature DC generated in vitro from normal donor and JMML-2 PBMC did not secrete IL-12 (o7.5 pg/150 000 cells). However, LPS-matured MoDC from a normal donor and LPS-matured DC from JMML-2 produced large amounts of IL-12 (210 pg/150 000 cells and 320 pg/ 150 000 cells, respectively). These results provide additional evidence for the stimulatory phenotype of mature DC generated from JMML-2 PBMC. In contrast, incubation of immature DC cultured from JMML-3 PBMC with LPS for 24 h resulted in the secretion of minimal amounts of IL-12 (15 pg/150 000 cells), significantly less than that observed in normal mature MoDC (Po0.05, Student's t-test). This abnormal secretion of IL-12 by JMML-3 DC following incubation with LPS is consistent with the flow cytometric data, demonstrating that the DC cultured from this patient were resistant to activation with LPS. The variability in the phenotypes of the DC generated from the three JMML patients might reflect the heterogeneity of this disorder. The immunostimulatory properties of DC cultured in vitro from JMML-2 PBMC were examined in a mixed leukocyte reaction using an IFN-g ELISpot assay. Responder PBMC were cultured with different DC stimulator cell populations at a ratio of 10:1, JMML-2-derived DC were able to stimulate allogeneic T cells as efficiently as normal MoDC, as measured by IFN-g secreted by activated T cells. However, culturing normal MoDC and leukemic DC with autologous T cells caused moderate and minimal IFN-g secretion, respectively (Figure 2a ). These data demonstrate that leukemic DC generated from JMML-2 PBMC were potent stimulators of allogeneic T lymphocytes.
We next attempted, with JMML-1 samples, to use the in vitro generated leukemic DC as stimulator cells to expand allogeneic JMML-specific T lymphocytes. The source of T cells was PBMC obtained approximately 1 month following allogeneic BMT. DNA chimerism studies had at this stage shown a 100% donor engraftment. Owing to limited starting cell numbers, after three rounds of stimulation using irradiated leukemic DC in the presence of IL-2, there were only sufficient T cells to perform a basic cytotoxicity assay. Cell killing by the expanded cytotoxic T lymphocytes (CTL) was determined using a lactate dehydrogenase (LDH) release assay (Promega, Madison, WI, USA). These preliminary results show that the CTL specifically lysed the leukemic JMML cells (Figure 2b ). Even at the very low effector:target ratio of 1:1, the CTL were able to lyse more than 15% of the leukemic targets. The CTL lysed the nonleukemic CD3 + T cells from the JMML patient to a lesser extent, and there was minimal CTL-directed lysis of allogeneic PBMC from an MHCmismatched normal donor. The data are consistent with a role for leukemic DC as stimulators of allogeneic T-cell responses against JMML cells, in an ex vivo setting following allogeneic BMT.
Longoni et al 8 HLA-DR + CD123 + DC subtypes than normal individuals (4.1 vs 0.5%, and 1.4 vs 0.6% total PBMC population, respectively). This suggests that JMML cells do spontaneously differentiate into DC in vivo, but it remains to be determined whether these CD11c + and CD123 + DC in JMML patients are functionally active immunostimulatory DC.
Our findings are in keeping with previous studies showing that monocytes from the majority of patients with the myeloid stem cell disorders AML 1 and CML 2 maintain their capacity to differentiate into phenotypic and functional DC. We had only three patients available for study and although results are rather heterogeneous, we have demonstrated that ex vivo generated leukemic DC derived Figure 1 Immunophenotype of DC cultured in vitro from normal control and JMML-2 PBMC. Plastic adherent PBMC were differentiated into immature DC with GM-CSF and IL-4 for 6 days. DC maturation was subsequently induced with LPS for 24 h. DC were harvested on day 6 (immature DC) or on day 7 following incubation with LPS (mature DC), stained with a panel of immunofluorescent antibodies and analyzed by flow cytometry. Cells were gated on large, granular cells, and gated cells are shown in the histogram plots. The black filled areas in histograms represent staining with the indicated monoclonal antibody, the unfilled white histograms indicate staining with an appropriate isotype control antibody. from two of these patients were immunostimulatory. The use of leukemic DC to stimulate allogeneic responses against JMML remains problematic because of the wide array of self-antigens presented, which are likely to induce potent graft-versus-host disease (GVHD) responses. However, there are several potential clinical applications arising from our data. Firstly, in vitro generated leukemic DC could be used for the stimulation of autologous PBMC (in an ex vivo setting) to generate antileukemic T cell lines for adoptive immunotherapy. In this regard, it is important to note that there is reduced reactivity against autologous PBMC with JMMLderived MoDC (Figure 2a) . This may be due to reduced T-cell number or function in JMML patients. However, the limited cytotoxicity assay suggests that the autologous population has the potential for antileukemic responses if stimulated by JMML-MoDC ex vivo. Secondly, DC differentiated in vitro from JMML cells may potentially be administered as a cellular leukemia vaccine in vivo, in the context of resistant disease and BMT failure. Thirdly, the data support the concept of generating allogeneic JMML-specific CTL lines from BMT donor T lymphocytes (T-cell source being either donor PBMC or activated T cells post engraftment). The T cells could be transduced with suicide genes to allow reversal of GVHD if it develops. Lastly, systemic treatment with cytokine therapy could potentially be used to induce immunostimulatory JMML DC in vivo, and would be applicable for patients with resistant disease post BMT. Further studies in a larger number of patients are warranted to confirm the immunostimulatory properties of JMML-derived DC.
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